TSE Panel Comments On Tissue Decontamination Protocols, Pooled Samples
This article was originally published in The Gray Sheet
Executive Summary
FDA should develop specific protocols for mitigating the transmission of Creutzfeld-Jakob disease and viral CJD in human cells, tissues and cellular and tissue-based products (HCT/Ps) for evaluation by the Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) at a future meeting, TSEAC voted June 26
You may also be interested in...
Tissue Framework Implementation Awaits Input From FDA Commissioner
The Center for Biologics Evaluation & Research expects to brief FDA Commissioner Mark McClellan on the agency's three-part tissue framework in the next several weeks
Tissue Framework Implementation Awaits Input From FDA Commissioner
The Center for Biologics Evaluation & Research expects to brief FDA Commissioner Mark McClellan on the agency's three-part tissue framework in the next several weeks
CJD Tissue/Cell Donor Draft Guidance Is Topic Of Upcoming TSE Meeting
FDA is requesting data to assess the impact of recommendations to reduce the risk of transmission of CJD and vCJD on the availability of human cells, tissues and cellular and tissue-based products (HCT/P)